tiprankstipranks
Sunshine Biopharma’s Strong Growth and Optimistic Outlook
Company Announcements

Sunshine Biopharma’s Strong Growth and Optimistic Outlook

Sunshine Biopharma, Inc. (SBFM) has released an update.

Don't Miss Our Christmas Offers:

Sunshine Biopharma Inc. experienced a significant year with a 14% average quarterly sales growth in 2023, reaching $24.09 million, partly due to the acquisition of Nora Pharma. The company also decreased its loss per share from $1.76 to $0.19 and furthered the development of two proprietary drugs. Despite challenges, like halting studies on an anticancer compound, Sunshine Biopharma is optimistic about continuing growth and profitability.

For further insights into SBFM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlySunshine Biopharma announces novel inhibitor for SARS Coronavirus
TheFlySunshine Biopharma announces research results on K1.1 mRNA product
TheFlySunshine Biopharma launches generic prescription drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App